-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
James P. Allison and Tasuku Honjo Jointly Awarded the Nobel Prize for Discovering Immunotherapy
Posted: December 2018 James P. Allison, PhD, and Tasuku Honjo, PhD, MD, were jointly awarded the 2018 Nobel Prize in Physiology or Medicine for their breakthrough accomplishments in cancer immunotherapy, leading to creation of a new highly effective and rapidly developing class of drugs, the immune checkpoint inhibitors, which have recently transformed the therapeutic landscape…
-
Fighting the Tobacco Scourge: Implementation of Tobacco-Control Measures Begets Public Health Success
By Jeffrey Drope, PhD; Cary Adams, MBA; Clifford E. Douglas, JD; Jacqui Drope, MPH; and Sonali Johnson, PhD Posted: December 2018 Clifford E. Douglas There is clear evidence of success in recent global efforts to curb tobacco use, the largest preventable cause of disease and premature death in the world. Since 2012, global cigarette consumption has…
-
Inaugural LATAM Awards
Posted: December 2018 The IASLC Latin America Conference on Lung Cancer in August featured a new awards presentation. The awards, sponsored by the IASLC Latin America Group (LATAM) were, in the words of LATAM Chair Luis E. Raez, MD, “for people who have not only moved forward the mission and vision of the IASLC globally…
-
Highlights from the NCI Post-Treatment Surveillance Workshop
Posted: December 2018 The National Cancer Institute (NCI) held a Post-Treatment Surveillance Workshop at the Shady Grove Campus this past March. In addition to lung cancer, the workshop focused on prostate cancer, breast cancer, colon cancer and testicular cancer. The lung cancer breakout session was co-chaired by Dr. Shakun Malik (NCI) and Dr. Geoff Oxnard…
-
2018 ASTRO Guideline for Palliative Thoracic Radiation Therapy for NSCLC: The Balance Between Curative and Palliative Radiotherapy
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous factors that may preclude this approach, including poor respiratory function and large tumor volume—both of which are surrogates for unacceptable radiation doses to normal lung…
-
The Vital and Evolving Role of Bronchoscopic Technologies in Lung Cancer Management
By Andrew R. Haas, MD, PhD Posted: October 2018 Lung cancer remains the leading global cause of cancer-related mortality.1 Due to the lack of symptoms at the time early-stage disease first manifests, the majority of patients still present with advanced-stage disease. Optimal treatment and patient outcome is incumbent on thorough radiographic and invasive staging. In…
-
Top Science in Lung Cancer Featured at WCLC 2018
By Kara Nyberg, PhD Posted: October 2018 The Presidential Symposium at the IASLC World Conference on Lung Cancer 2018 (WCLC) showcased the top five scientific abstracts highlighting progress in detecting and treating different forms of lung cancer and mesothelioma. These presentations featured four positive clinical trials that advance current treatment standards and one negative clinical…
-
Living in the “Gray Zone”: Entering a New Age in Radiation Therapy for Patients with Lung Cancer
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection of optimal therapies for individual patients, including stereotactic body radiation therapy (SBRT), is more nuanced. With the advent of improvements in technology, more multidisciplinary approaches…
-
A Review of CancerSEEK
By Pierre P. Massion, MD Posted: October 2018 Early detection is key to disease management. For example, there are numerous data in hypertension, diabetes, coronary artery disease, and renal dysfunction showing strong correlation between early diagnosis and improved outcome.1 Noninvasive means of early detection of cancer is around the corner.2-4 Recent research has positioned the…
-
The Treatment of Patients with Oligometastatic Lung Cancer
By Anne-Marie C. Dingemans, MD, PhD, and Lizza E.L. Hendriks, MD, PhD Posted: October 2018 Patients with stage IV NSCLC are generally viewed as having incurable disease; however, for years, patients presenting with a solitary brain or adrenal metastasis have been treated with local ablative treatment (LAT) with curative intent, and multiple series have shown…
View ILCN Archives
Provider Resources
Popular Articles